The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Biomarin Pharmaceutical competitive analysis

Loading summary...

Latest patents of Biomarin Pharmaceutical opposed by its competitors

Explore Biomarin Pharmaceutical's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP3328416
Mar 13, 2024Use Of C-Type Natriuretic Peptide Variants To Treat Skeletal Dysplasia3
EP3461503
May 11, 2022Methods Of Administering Tetrahydrobiopterin, Associated Compositions, And Methods Of Measuring5
EP3138566
Jan 26, 2022Treatment Of Phenylketonuria With Bh43
EP3175863
Dec 1, 2021Variants Of C-Type Natriuretic Peptide2
EP2545939
Dec 16, 2020Methods Of Administering Tetrahydrobiopterin, Associated Compositions, And Methods Of Measuring5

Latest PTAB cases involving Biomarin Pharmaceutical

Discover the latest PTAB cases involving Biomarin Pharmaceutical, highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 13, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Biomarin Pharmaceutical

IPR2013-00534Aug 28, 2013BIOMARIN PHARMACEUTICALGENZYME THERAPEUTIC PRODUCTS PARTNERSHIPFinal Written Decision
IPR2013-00535Aug 28, 2013BIOMARIN PHARMACEUTICALDUKE UNIVERSITYFinal Written Decision
IPR2013-00537Aug 28, 2013BIOMARIN PHARMACEUTICALGENZYME THERAPEUTIC PRODUCTS PARTNERSHIPFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Biomarin Pharmaceutical with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BIOMARIN PHARMACEUTICAL - 183 -
BETAPHARM ARZNEIMITTEL13 - - -
DIPHARMA3 - - -
STADA ARZNEIMITTEL11028 - -